Revolution Medicines (RVMD) stock
Last close $159.43 on 2026-11-19 (-0.24%) · Sector: Healthcare
Revolution Medicines is a biotech company that discovers and develops new cancer drugs aimed at hard-to-target proteins that drive tumors. Like many drug developers, it spends heavily on research and testing, so it earns little revenue today and relies on its cash and investor funding to keep going.
The business is still in the spending phase: revenue is tiny at $0.2 billion over the last twelve months, and losses have grown each quarter. The stock has still returned 128.1% over the past year, far beyond the S&P 500's 9.7%, but it sits 28.9% below its 52-week high and is below both its 50-day and 200-day averages. Insiders sold about $60.0 million of stock over the last 90 days and made no purchases, and the stock has mostly fallen the day after earnings releases.
Key numbers
- Market cap: $34.3B
- Revenue (last 12 months): $0.20B
- Gross margin: 99.8%
- Operating margin: -545.0%
- P/S: 171.3
- Debt to equity: 0.00
- Current ratio: 8.29
Performance and risk
1-year return +128.1% vs S&P 500 +9.7% · volatility 68.8% (S&P 500 13.8%) · largest drop -27.9% · beta 1.34
Stock move the day after earnings
- 2026-02-25: -1.1%
- 2026-05-06: -5.7%
- 2026-08-05: +0.3%
- 2026-11-04: -11.0%
Insider trades (12 months)
Bought $0.0M · sold $161.7M
RVMD stock research · RVMD options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.